Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Adrenomedullin | 2 | 2021 | 217 | 0.87 | Why? |
| Renal Replacement Therapy | 2 | 2021 | 1530 | 0.84 | Why? |
| Protein Precursors | 2 | 2021 | 425 | 0.80 | Why? |
| Sepsis | 10 | 2020 | 3517 | 0.78 | Why? |
| HLA-DR alpha-Chains | 1 | 2017 | 8 | 0.71 | Why? |
| Shock, Septic | 3 | 2018 | 1313 | 0.70 | Why? |
| Adsorption | 1 | 2018 | 261 | 0.70 | Why? |
| Neisseria meningitidis, Serogroup B | 1 | 2018 | 66 | 0.70 | Why? |
| Hemoglobinuria, Paroxysmal | 1 | 2018 | 116 | 0.64 | Why? |
| Albumins | 1 | 2018 | 324 | 0.63 | Why? |
| Meningococcal Infections | 1 | 2018 | 216 | 0.57 | Why? |
| Hemoperfusion | 1 | 2017 | 260 | 0.51 | Why? |
| Immune Tolerance | 1 | 2017 | 608 | 0.48 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.37 | Why? |
| Plasma | 1 | 2018 | 1809 | 0.36 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.35 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.33 | Why? |
| Anti-Infective Agents | 1 | 2018 | 1766 | 0.32 | Why? |
| Acute Kidney Injury | 4 | 2021 | 5762 | 0.32 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.30 | Why? |
| Monocytes | 1 | 2017 | 2978 | 0.28 | Why? |
| Critical Illness | 6 | 2021 | 17281 | 0.24 | Why? |
| Biomarkers | 6 | 2021 | 23361 | 0.21 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.20 | Why? |
| Estradiol | 1 | 2021 | 250 | 0.20 | Why? |
| Arginine | 2 | 2018 | 377 | 0.18 | Why? |
| Acidosis, Lactic | 1 | 2018 | 83 | 0.18 | Why? |
| Dialysis | 1 | 2018 | 45 | 0.18 | Why? |
| Thienamycins | 1 | 2018 | 72 | 0.18 | Why? |
| Peritonitis | 1 | 2019 | 217 | 0.16 | Why? |
| Germany | 6 | 2021 | 9196 | 0.16 | Why? |
| Testosterone | 1 | 2021 | 596 | 0.15 | Why? |
| Ceftazidime | 1 | 2017 | 134 | 0.15 | Why? |
| Vaccines, Conjugate | 1 | 2018 | 328 | 0.15 | Why? |
| Meningococcal Vaccines | 1 | 2018 | 225 | 0.14 | Why? |
| In Vitro Techniques | 1 | 2018 | 1027 | 0.14 | Why? |
| Polymers | 1 | 2018 | 507 | 0.13 | Why? |
| Lipopolysaccharides | 1 | 2017 | 848 | 0.12 | Why? |
| Organ Dysfunction Scores | 4 | 2018 | 1475 | 0.11 | Why? |
| Hospitals, University | 2 | 2021 | 4173 | 0.11 | Why? |
| Nitric Oxide | 1 | 2017 | 769 | 0.10 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.10 | Why? |
| Prospective Studies | 7 | 2020 | 43301 | 0.10 | Why? |
| Endothelium, Vascular | 1 | 2020 | 1751 | 0.09 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.09 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.09 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.09 | Why? |
| Autopsy | 1 | 2020 | 3495 | 0.09 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.09 | Why? |
| Peptide Fragments | 1 | 2018 | 2075 | 0.08 | Why? |
| Immunoglobulin A | 1 | 2019 | 3567 | 0.08 | Why? |
| Immunoglobulins, Intravenous | 1 | 2019 | 2705 | 0.08 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.07 | Why? |
| Female | 15 | 2021 | 380317 | 0.07 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.07 | Why? |
| Immunotherapy | 1 | 2019 | 2421 | 0.07 | Why? |
| Lactic Acid | 2 | 2018 | 393 | 0.07 | Why? |
| Monte Carlo Method | 2 | 2018 | 577 | 0.07 | Why? |
| Aged | 12 | 2021 | 215776 | 0.07 | Why? |
| Male | 14 | 2021 | 367725 | 0.06 | Why? |
| Humans | 20 | 2021 | 930598 | 0.06 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2019 | 9091 | 0.05 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.05 | Why? |
| Hypogonadism | 1 | 2021 | 196 | 0.05 | Why? |
| Renal Dialysis | 1 | 2017 | 4358 | 0.05 | Why? |
| Metabolic Clearance Rate | 1 | 2018 | 110 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.05 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.05 | Why? |
| Microbial Sensitivity Tests | 2 | 2018 | 2886 | 0.05 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.04 | Why? |
| Homoarginine | 1 | 2017 | 7 | 0.04 | Why? |
| Nitric Oxide Synthase | 1 | 2017 | 37 | 0.04 | Why? |
| Amidohydrolases | 1 | 2017 | 30 | 0.04 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.04 | Why? |
| Early Termination of Clinical Trials | 1 | 2020 | 1256 | 0.04 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.04 | Why? |
| Calcitonin | 1 | 2018 | 201 | 0.04 | Why? |
| Influenza, Human | 1 | 2021 | 10779 | 0.04 | Why? |
| APACHE | 1 | 2018 | 682 | 0.04 | Why? |
| Analysis of Variance | 1 | 2018 | 950 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2019 | 21571 | 0.04 | Why? |
| Infusions, Intravenous | 1 | 2019 | 1224 | 0.03 | Why? |
| Austria | 1 | 2019 | 1259 | 0.03 | Why? |
| Sex Distribution | 1 | 2021 | 2083 | 0.03 | Why? |
| Shock | 1 | 2020 | 1868 | 0.03 | Why? |
| Pseudomonas aeruginosa | 1 | 2017 | 652 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2019 | 2437 | 0.03 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.03 | Why? |
| Adult | 5 | 2020 | 244371 | 0.03 | Why? |
| Kinetics | 1 | 2017 | 3238 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Kidney | 1 | 2021 | 3648 | 0.02 | Why? |
| Liver | 1 | 2021 | 4007 | 0.02 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2019 | 3755 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Patient Selection | 1 | 2019 | 4560 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.02 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 5002 | 0.02 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2018 | 7972 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.00 | Why? |
Nierhaus's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(121)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1135)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_